Press "Enter" to skip to content

Europe Dipeptide Peptidase 4 (DPP-4) inhibitors Market 2019 | Rising Status of Key Players, Industry Size & Share, Growth Factors, New Technologies Revenue Forecast by 2024

Europe

The “Europe Dipeptide Peptidase 4 (DPP-4) inhibitors Market” report 2019 provides information for market players, stakeholders, investors, and business strategists to achieve a leading position the market. It maintains the record of Unusual growth strategies adopted by various companies are creating new standards for competition in the global Europe Dipeptide Peptidase 4 (DPP-4) inhibitors market. Businesses around the world are aiming at increasing their profit margin and establishing a stronghold in the global market. The impact of prevailing regulatory scenario on both regional and worldwide Europe Dipeptide Peptidase 4 (DPP-4) inhibitors market is provided in detail in the report.

Get a Sample Copy of the Report – https://www.industryresearch.co/enquiry/request-sample/14245118  

Europe Dipeptide Peptidase 4 (DPP-4) inhibitors Market Covers Key Players:

  • Merck and Co.
  • AstraZeneca
  • Bristol Myers Squibb
  • Novartis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Boehringer Ingelheim

    Market Overview:

  • – The diabetes spending in Europe is 9% of the total healthcare expenditure. Spending on diabetes largely vary among countries in Europe. It ranges from EUR 312 per capita in the Republic of Macedonia, to EUR 6,896 per capita in Norway.
  • – Similarly, the prevalence is also highly varied across Europe, ranging from 2.8% in Albania to 9.8% in Portugal. In high-income countries, diabetes is one of the leading causes of cardiovascular disease, blindness, kidney failure, and lower limb amputation.

    Report Highlights:

    • The report provides a detailed analysis on current and future market trends to identify the investment opportunities
    • Market forecasts till 2024, using estimated market values as the base numbers
    • Key market trends across the business segments, Regions and Countries
    • Key developments and strategies observed in the market
    • Market Dynamics such as Drivers, Restraints, Opportunities and other trends
    • In-depth company profiles of key players and upcoming prominent players
    • Growth prospects among the emerging nations through 2024
    • Europe Dipeptide Peptidase 4 (DPP-4) inhibitors Market opportunities and recommendations for new investments

    For More Information or Query or Customization Before Buying, Visit athttps://www.industryresearch.co/enquiry/pre-order-enquiry/14245118

    Scope of the Report:

  • The DPP-4 inhibitors market is segmented by brands and covers the following brands, namely, Januvia, Onglyza/Kombiglyze, Tradjenta, Nesina, Galvus, and other brands. The report is segmented by geography.

    Key Market Trends:

    Januvia Had Registered a Negative CAGR in the Historic Period.

    – The DPP-4 inhibitor drugs are Tradjenta (linagliptin), Onglyza (saxagliptin), Januvia (sitagliptin), Nesina (Alogliptin), and Glavus(Vildagliptin). The European DPP-4 market is expected to register a CAGR of 4.9%, over the forecast period (2018-2023).
    – Januvia holds the highest share in the DPP-4 market. However, it is expected to decrease during the forecast period, and Tradjenta is expected to gain market share, due to increased efficacy.
    – The market value for Januvia had registered negative CAGR in the European region, due to the decrease in global revenue of drug. Additionally, it is facing pricing pressure due to higher discounts and rebates to maintain good managed care coverage in Europe.

    Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is Expected to Register a CAGR of 3.8%

    – The market is directly proportional to the growing type 2 diabetic population. In most of the cases, DPP-4 are the second line of drugs prescribed for type 2 patients.
    – Over the years, the European diabetic population increased tremendously, and type 2 population accounts for almost 90% of the diabetic population. The growth in diabetic population is due to it being a lifestyle disease.

    Purchase this Report (Price 4000 USD for single user license) – https://www.industryresearch.co/purchase/14245118

    Detailed TOC of Europe Dipeptide Peptidase 4 (DPP-4) inhibitors Market Report 2019-2024:

    1 INTRODUCTION
    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study

    2 RESEARCH METHODOLOGY

    3 EXECUTIVE SUMMARY

    4 MARKET DYNAMICS
    4.1 Market Overview
    4.2 Drivers
    4.3 Restraints
    4.4 Porter’s Five Forces Analysis
    4.4.1 Bargaining Power of Suppliers
    4.4.2 Bargaining Power of Consumers
    4.4.3 Threat of New Entrants
    4.4.4 Threat of Substitute Products and Services
    4.4.5 Intensity of Competitive Rivalry

    5 MARKET SEGMENTATION
    5.1 By Drug
    5.1.1 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume, 2012-2024)
    5.1.1.1 Januvia (Sitagliptin)
    5.1.1.2 Onglyza (Saxagliptin)
    5.1.1.3 Tradjenta (Linagliptin)
    5.1.1.4 Vipidia/Nesina (Alogliptin)
    5.1.1.5 Galvus (Vildagliptin)
    5.1.1.6 Other DPP – 4 Drugs
    5.2 Geography
    5.2.1 Europe
    5.2.1.1 France (Value and Volume, 2012-2024)
    5.2.1.1.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.1.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.2 Germany (Value and Volume, 2012-2024)
    5.2.1.2.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.2.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.3 Italy (Value and Volume, 2012-2024)
    5.2.1.3.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.3.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.4 Spain (Value and Volume, 2012-2024)
    5.2.1.4.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.4.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.5 United Kingdom (Value and Volume, 2012-2024)
    5.2.1.5.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.5.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.6 Russia (Value and Volume, 2012-2024)
    5.2.1.6.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.6.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)
    5.2.1.7 Rest of Europe (Value and Volume, 2012-2024)
    5.2.1.7.1 By Drug (Januvia, Onglyza, Tradjenta, Vipidia, Galvus)
    5.2.1.7.2 By Company (Merck, AstraZeneca, Novartis, Eli Lilly & Boehringer Ingelheim, Takeda Pharmaceutical)

    6 MARKET INDICATORS
    6.1 Type-1 Diabetes Population (2012-2024)
    6.2 Type-2 Diabetes Population (2012-2024)

    7 COMPETITIVE LANDSCAPE
    7.1 Company Profiles
    7.1.1 Merck and Co.
    7.1.2 AstraZeneca
    7.1.3 Bristol Myers Squibb
    7.1.4 Novartis
    7.1.5 Takeda Pharmaceuticals
    7.1.6 Eli Lilly
    7.1.7 Boehringer Ingelheim
    7.2 Company Share Analysis
    7.2.1 Merck and Co.
    7.2.2 AstraZeneca
    7.2.3 Takeda Pharmaceuticals
    7.2.4 Novartis
    7.2.5 Eli Lilly & Boehringer Ingelheim

    8 MARKET OPPORTUNITIES AND FUTURE TRENDS

     

    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Speed Doors Market Share, Size 2019 Movements by Trend Analysis, Progression Status, Revenue Expectation to 2024 | Research Report by Industry Research Biz

    Commercial Aircraft Battery Market 2019 Industry Business Challenges, Share, Geographical Segmentation, Consumption Status and Opportunity Analysis: World Market Outlook to 2024

    Cosmetic Jars Packaging Industry 2019 Global Market Growth, Trends, Revenue, Share and Demands Research Report

    Global Synthetic Fibers Market Research Report 2019-2024 | Market Share, Size, and Revenue by Types, Applications, and Regional Forecast

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *